Efficacy and safety of antiretroviral regimens including raltegravir to treat HIV-infected patients with hemophilia
-
- Xiao Hong
- Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University
-
- Xue Yile
- Department of AIDS and STD, Shanghai Municipal Center for Disease Control and Prevention
-
- Gu Shiming
- Department of Clinical Medical Laboratory, Shanghai Public Health Clinical Center, Fudan University
-
- Wang Jiangrong
- Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University
-
- Sun Hongqing
- Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University
-
- Lu Hongzhou
- Department of Infectious Diseases, Shanghai Public Health Clinical Center, Fudan University
Search this article
Abstract
When treating HIV-infected patients with hemophilia, adverse drug reactions and interactions and the effect of treatment on bleeding disorders must be considered. Raltegravir is the first HIV integrase inhibitor, but its use in patients with hemophilia is rarely reported. Nine HIV-positive patients with hemophilia were retrospectively studied with a focus on the virological response, changes in the CD4 count, the tendency to bleed, and the response to replacement therapy before and after raltegravir-based antiretroviral therapy (ART). The nine patients were highly treatment-experienced patients and they received raltegravir-based ART for at least nine months. The patients had their own reasons for changing to raltegravir-based ART. During treatment, the CD4 count increased progressively in four patients, with a median absolute increase of 233 cells/mm3, while the count stabilized in the remaining five patients. Two previous recipients of lopinavir/ritonavir (LPV/r) who failed to respond to lamivudine (3TC) + zidovudine (ZDV) + efavirenz (EFV) had a viral rebound. Genotyping indicated multidrug resistance to nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs). A pattern of resistance to raltegravir was evident, including the primary mutation N155H and the secondary mutation T97A. In the two patients, the tendency to bleed decreased markedly and monthly usage of clotting factor VIII decreased significantly decreased. In the remaining seven patients, the viral load remained < 40 copies/mL, there was no evidence of an increased tendency to bleed, and no evidence of changes in the response to replacement therapy. All of the patients had a stable condition with no signs of disease progression and no serious adverse reactions. Results indicated that Raltegravir-based therapy offered a safe and well-tolerated option for HIV-positive patients with hemophilia.
Journal
-
- BioScience Trends
-
BioScience Trends 10 (1), 42-46, 2016
International Research and Cooperation Association for Bio & Socio-Sciences Advancement
